InfanDx AG
InfanDx receives U.S. patent for its core technology on diagnosis of neonatal encephalopathy
DGAP-News: InfanDx AG
/ Key word(s): Patent
InfanDx receives U.S. patent for its core technology on diagnosis of neonatal encephalopathy The HypoxE-test(R) is based on metabolomic biomarkers to rapidly diagnose brain damage, which can result from oxygen deficit during delivery (asphyxia neonatorum). This way, affected newborns can be treated in time with an established therapeutic intervention, hypothermia, which limits or completely prevents permanent damage. However, this treatment has to be initiated within six hours after birth. InfanDx aims to offer the first test worldwide to reliably diagnose affected babies within this time window. “We are excited that we have now received a particularly clear and broad protection for our novel test also in the U.S. as well. Despite the difficult legal situation for biomarker-based tests following the so-called Prometheus ruling in the U.S., we have managed to obtain two essential patents for our test here. Receiving patent protection in such an important market clearly signals our innovative strength,” said Ron Meyer, CEO of InfanDx. InfanDx plans to market the test as a user-friendly disposable test cartridge together with a dedicated diagnostic device. This will allow for a rapid and easy diagnosis directly in the delivery room. Of the 125 million newborns worldwide each year, 5 – 10 % are at risk to have suffered perinatal asphyxia.
InfanDx AG Media contact
09.01.2020 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |